Traws Pharma Files 8-K/A Amendment

TL;DR

Traws Pharma (fka Onconova) filed an 8-K/A amendment on 6/17/24 for financial statements.

AI Summary

Traws Pharma, Inc. filed an amendment (8-K/A) on June 17, 2024, to a previous report. The filing pertains to financial statements and exhibits. The company, formerly known as Onconova Therapeutics, Inc., is incorporated in Delaware and headquartered in Newtown, PA.

Why It Matters

This amendment updates the company's filings with the SEC, providing updated information on its financial statements and exhibits.

Risk Assessment

Risk Level: low — This filing is an amendment to a previous report and primarily concerns financial statements and exhibits, not a new event or significant financial change.

Key Numbers

• 001-36020 — SEC File Number (Identifies the company's SEC filing history)
• 22-3627252 — IRS Employer Identification No. (Company's tax identification number)

Key Players & Entities

• Traws Pharma, Inc. (company) — Registrant
• Onconova Therapeutics, Inc. (company) — Former company name
• June 17, 2024 (date) — Date of report
• Delaware (jurisdiction) — State of incorporation
• Newtown, PA (location) — Business address

FAQ

Filing Documents

• tm2416775d1_8ka.htm (8-K/A) — 30KB
• tm2416775d1_ex23-1.htm (EX-23.1) — 6KB
• tm2416775d1_ex99-1.htm (EX-99.1) — 242KB
• tm2416775d1_ex99-2.htm (EX-99.2) — 173KB
• tm2416775d1_ex99-3.htm (EX-99.3) — 172KB
• 0001104659-24-072379.txt ( ) — 869KB
• tmb-20240617.xsd (EX-101.SCH) — 3KB
• tmb-20240617_lab.xml (EX-101.LAB) — 33KB
• tmb-20240617_pre.xml (EX-101.PRE) — 22KB
• tm2416775d1_8ka_htm.xml (XML) — 4KB

Financial Statements and Exhibits

Financial Statements and Exhibits. (a) Financial statements of businesses acquired . The audited financial statements and accompanying notes of Trawsfynydd as of and for the years ended December 31, 2023 and 2022 are filed as Exhibit 99.1 to this Current Report on Form 8-K/A and incorporated herein by reference. The unaudited financial statements and accompanying notes of Trawsfynydd as of and for the three months ended March 31, 2024 and 2023 are filed as Exhibit 99.2 to this Current Report on Form 8-K/A and incorporated herein by reference. (b) Pro forma financial information . The unaudited pro forma condensed combined balance sheet as of March 31, 2024, the unaudited pro forma condensed combined statement of operations for the three months ended March 31, 2024, the unaudited pro forma combined statement of operations for the year ended December 31, 2023, and the related notes of Traws Pharma, Inc. with respect to the transaction described above, are filed as Exhibit 99.3 to this Current Report on Form 8-K/A and incorporated herein by reference. (d) Exhibits . Exhibit No. Exhibit 23.1 Consent of EisnerAmper LLP, the independent auditors of Trawsfynydd Therapeutics, Inc. 99.1 Audited financial statements of Trawsfynydd , as of December 31, 2023 and 2022 and for the years then ended. 99.2 Unaudited financial statements of Trawsfynydd , as of and for the three months ended March 31, 2024 and 2023. 99.3 Unaudited pro form condensed combined financial information of Traws Pharma, Inc. as of and for the three months ended March 31, 2024, and for the year ended December 31, 2023. 104 The cover page from this Current Report on Form 8-K, formatted in Inline XBRL. 1 SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: June 17, 2024 TRAWS PHARMA, INC. By: /s/ MARK GUERIN Name: Mark Guerin

View Full Filing

View this 8-K/A filing on SEC EDGAR